{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:36:26Z","timestamp":1787891786517,"version":"build-2784847793"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["1R01 HL137355"],"award-info":[{"award-number":["1R01 HL137355"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["1R01 HL107110"],"award-info":[{"award-number":["1R01 HL107110"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["1R01 HL134558"],"award-info":[{"award-number":["1R01 HL134558"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["5R01 CA136387"],"award-info":[{"award-number":["5R01 CA136387"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["5UM1 HL113460"],"award-info":[{"award-number":["5UM1 HL113460"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite limited human data, there is a growing interest in the use of stem cell therapy (SCT) for erectile dysfunction (ED).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To determine the effect of transendocardial stem cell injection on erectile function on men with cardiomyopathy and ED.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used International Index of Erectile Function (IIEF) scores collected from men enrolled in 3 separate randomized controlled trials: Comparison of Allogeneic vs Autologous Bone Marrow\u2013Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy (POSEIDON), Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic Cardiomyopathy (TAC-HFT), and Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (TRIDENT). These trials recruited patients with ischemic cardiomyopathy and ejection fraction less than 50%. Inclusion and exclusion criteria were identical in all 3 trials. The primary intervention in these trials included transendocardial stem cell injection of stem cells or placebo via cardiac catheterization. The follow-up period was 1 year. IIEF data were collected at baseline and at multiple time points in each trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>We investigated erectile function over time based on cell dose, cell source (autologous vs allogenic), cell type (mesenchymal stem cells vs bone marrow mononuclear cells), and comparing men who received SCT with those who received placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 36 men were identified with complete IIEF data. 8 men received placebo injection, and 28 received SCT. The median age was 66.5 years. Comorbidities were similar among all men. Analysis was performed on men with ED, defined by an IIEF-EF score of 24 or less. In the placebo and all-comer SCT group, the median IIEF-EF score was 5 [1\u20138] and 5 [1\u201315] at baseline and was 3.5 [3\u20135.8] and 7 [1\u201318] at 12 months (P &amp;gt; .05). When analyzed by cell dose, the IIEF-EF score in men who received 200 million cells increased significantly over 12 months (14 [4\u201323] to 20 [15\u201324.5], P = .014.) Similarly, an autologous cell source resulted in a similar increase from baseline to 12 months (14 [3.8\u201323.3] to 20 [12\u201322], P = .030).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>Erectile function may improve after systemic delivery of SCT in men with ischemic cardiomyopathy and at least mild ED.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths &amp; Limitations<\/jats:title>\n                  <jats:p>This post hoc analysis is the first to investigate the effect of SCT on erectile function using randomized, placebo-controlled data. Weaknesses include that ED was not a primary end point, and men were not originally recruited based on erectile function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Future trials on systemic delivery of SCT for ED should focus on high cell dose and autologous cell source, as these seem to provide the best response in men with at least mild ED.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1016\/j.jsxm.2020.01.003","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T11:43:22Z","timestamp":1581507802000},"page":"695-701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Effect of Transendocardial Stem Cell Injection on Erectile Function in Men with Cardiomyopathy: Results From the TRIDENT, POSEIDON, and TAC-HFT Trials"],"prefix":"10.1093","volume":"17","author":[{"given":"Jesse","family":"Ory","sequence":"first","affiliation":[{"name":"Department of Urology , Halifax, NS , Canada"},{"name":"Dalhousie University , Halifax, NS , Canada"},{"name":"Department of Urology , Miami, FL , USA"},{"name":"Miller School of Medicine , Miami, FL , USA"},{"name":"University of Miami , Miami, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell G.","family":"Saltzman","sequence":"additional","affiliation":[{"name":"Miller School of Medicine , Miami, FL , USA"},{"name":"Interdisciplinary Stem Cell Institute , Miami, FL , USA"},{"name":"University of Miami , Miami, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Blachman-Braun","sequence":"additional","affiliation":[{"name":"Miller School of Medicine , Miami, FL , USA"},{"name":"Interdisciplinary Stem Cell Institute , Miami, FL , USA"},{"name":"University of Miami , Miami, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Dadoun","sequence":"additional","affiliation":[{"name":"Miller School of Medicine , Miami, FL , USA"},{"name":"Interdisciplinary Stem Cell Institute , Miami, FL , USA"},{"name":"University of Miami , Miami, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darcy L.","family":"DiFede","sequence":"additional","affiliation":[{"name":"Miller School of Medicine , Miami, FL , USA"},{"name":"Interdisciplinary Stem Cell Institute , Miami, FL , USA"},{"name":"University of Miami , Miami, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Premer","sequence":"additional","affiliation":[{"name":"Miller School of Medicine , Miami, FL , USA"},{"name":"Interdisciplinary Stem Cell Institute , Miami, FL , USA"},{"name":"University of Miami , Miami, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Hurwitz","sequence":"additional","affiliation":[{"name":"Behavioral Medicine Research Center , Miami, FL , USA"},{"name":"University of Miami , Miami, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Hare","sequence":"additional","affiliation":[{"name":"Miller School of Medicine , Miami, FL , USA"},{"name":"Interdisciplinary Stem Cell Institute , Miami, FL , USA"},{"name":"University of Miami , Miami, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjith","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Department of Urology , Miami, FL , USA"},{"name":"Miller School of Medicine , Miami, FL , USA"},{"name":"University of Miami , Miami, FL , USA"},{"name":"Miller School of Medicine , Miami, FL , USA"},{"name":"Interdisciplinary Stem Cell Institute , Miami, FL , USA"},{"name":"University of Miami , Miami, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"2023011111082136100_bib1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0022-5347(05)67900-1","article-title":"Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study","volume":"163","author":"Johannes","year":"2000","journal-title":"J Urol"},{"key":"2023011111082136100_bib2","doi-asserted-by":"crossref","first-page":"16003","DOI":"10.1038\/nrdp.2016.3","article-title":"Erectile dysfunction","volume":"2","author":"Yafi","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2023011111082136100_bib3","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1046\/j.1464-410x.2001.02211.x","article-title":"Vascular risk factors and erectile dysfunction","volume":"87","author":"Sullivan","year":"2001","journal-title":"BJU Int"},{"key":"2023011111082136100_bib4","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1111\/j.1743-6109.2010.01779.x","article-title":"Cardiovascular aspects of sexual medicine","volume":"7","author":"Jackson","year":"2010","journal-title":"J Sex Med"},{"key":"2023011111082136100_bib5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5152\/tud.2017.70482","article-title":"Erectile dysfunction in the elderly male","volume":"43","author":"G\u00f6k\u00e7e","year":"2017","journal-title":"Turk J Urol"},{"key":"2023011111082136100_bib6","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1080\/14712598.2018.1534955","article-title":"Advances in stem cell therapy for erectile dysfunction","volume":"18","author":"Gur","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"2023011111082136100_bib7","doi-asserted-by":"crossref","first-page":"e92825","DOI":"10.1371\/journal.pone.0092825","article-title":"Human urine-derived stem cells alone or genetically-modified with FGF2 Improve type 2 diabetic erectile dysfunction in a rat model","volume":"9","author":"Ouyang","year":"2014","journal-title":"PLoS One"},{"key":"2023011111082136100_bib8","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/j.1743-6109.2012.02753.x","article-title":"Effects of intravenous injection of adipose-derived stem cells in a rat model of radiation therapy-induced erectile dysfunction","volume":"9","author":"Qiu","year":"2012","journal-title":"J Sex Med"},{"key":"2023011111082136100_bib9","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/gerona\/glx137","article-title":"Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial","volume":"72","author":"Tompkins","year":"2017","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2023011111082136100_bib10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.sxmr.2019.08.003","article-title":"A Systematic Review of Human Trials Using Stem Cell Therapy for Erectile Dysfunction","volume":"8","author":"Lokeshwar","year":"2020","journal-title":"Sex Med Rev"},{"key":"2023011111082136100_bib11","first-page":"150","article-title":"Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases","volume":"8","author":"Bahk","year":"2010","journal-title":"Exp Clin Transpl"},{"key":"2023011111082136100_bib12","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1001\/jama.2012.25321","article-title":"Comparison of allogeneic vs autologous bone marrow\u2013derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial","volume":"308","author":"Hare","year":"2012","journal-title":"JAMA"},{"key":"2023011111082136100_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jama.2013.282909","article-title":"Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial","volume":"311","author":"Heldman","year":"2014","journal-title":"JAMA"},{"key":"2023011111082136100_bib14","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1161\/CIRCRESAHA.117.311827","article-title":"Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study)","volume":"121","author":"Florea","year":"2017","journal-title":"Circ Res"},{"key":"2023011111082136100_bib15","doi-asserted-by":"crossref","first-page":"e008588","DOI":"10.1161\/JAHA.118.008588","article-title":"Endothelial Dysfunction, Increased Arterial Stiffness, and Cardiovascular Risk Prediction in Patients With Coronary Artery Disease: FMD-J (Flow-Mediated Dilation Japan) Study A","volume":"7","author":"Maruhashi","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2023011111082136100_bib16","doi-asserted-by":"crossref","first-page":"9847015","DOI":"10.1155\/2018\/9847015","article-title":"Insights into Endothelial Progenitor Cells: Origin, Classification, Potentials, and Prospects","volume":"2018","author":"Chopra","year":"2018","journal-title":"Stem Cells Int"},{"key":"2023011111082136100_bib17","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.eururo.2011.07.053","article-title":"Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale","volume":"60","author":"Rosen","year":"2011","journal-title":"Eur Urol"},{"key":"2023011111082136100_bib18","doi-asserted-by":"crossref","first-page":"203.e6","DOI":"10.1016\/j.urology.2018.06.018","article-title":"A 12-Month Follow-up After a Single Intracavernous Injection of Autologous Adipose-Derived Regenerative Cells in Patients with Erectile Dysfunction Following Radical Prostatectomy: An Open-Label Phase I Clinical Trial","volume":"121","author":"Haahr","year":"2018","journal-title":"Urology"},{"key":"2023011111082136100_bib19","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1111\/j.1582-4934.2012.01594.x","article-title":"Transendocardial cell injection is not superior to intracoronary infusion in a porcine model of ischaemic cardiomyopathy: a study on delivery efficiency","volume":"16","author":"van der Spoel","year":"2012","journal-title":"J Cell Mol Med"},{"key":"2023011111082136100_bib20","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/01.CIR.0000084828.50310.6A","article-title":"Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution","volume":"108","author":"Barbash","year":"2003","journal-title":"Circulation"},{"key":"2023011111082136100_bib21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/ijir.2011.38","article-title":"Tracking intracavernously injected adipose-derived stem cells to bone marrow","volume":"23","author":"Lin","year":"2011","journal-title":"Int J Impot Res"},{"key":"2023011111082136100_bib22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1745-7262.2007.00265.x","article-title":"Magnetic resonance evaluation of human mesenchymal stem cells in corpus cavernosa of rats and rabbits","volume":"9","author":"Song","year":"2007","journal-title":"Asian J Androl"},{"key":"2023011111082136100_bib23","first-page":"e8","article-title":"Effects of Stem Cell Treatment in Human Patients With Peyronie Disease","volume":"115","author":"Levy","year":"2015","journal-title":"J Am Osteopath Assoc"},{"key":"2023011111082136100_bib24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.eururo.2013.08.019","article-title":"Ten-year outcomes of sexual function after radical prostatectomy: results of a prospective longitudinal study","volume":"65","author":"Sivarajan","year":"2014","journal-title":"Eur Urol"},{"key":"2023011111082136100_bib25","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","article-title":"An analysis of the natural history of Peyronie's disease","volume":"175","author":"Mulhall","year":"2006","journal-title":"J Urol"},{"key":"2023011111082136100_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/0253-7176.116232","article-title":"How to calculate sample size for different study designs in medical research?","volume":"35","author":"Charan","year":"2013","journal-title":"Indian J Psychol Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174360952030028X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174360952030028X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/17\/4\/695\/48527123\/jsm_17_4_695.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/17\/4\/695\/48527123\/jsm_17_4_695.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T14:44:01Z","timestamp":1675953841000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/17\/4\/695\/6973794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,2,11]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2020.01.003","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2020,2,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effect of Transendocardial Stem Cell Injection on Erectile Function in Men With Cardiomyopathy: Results From the TRIDENT, POSEIDON, and TAC-HFT Trials","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2020.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}